EWTX Edgewise Therapeutics
- 16.930
- -0.180-1.05%
Edgewise Therapeutics News
Edgewise Therapeutics | 8-K: Current report
Edgewise Therapeutics | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
Edgewise Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Edgewise Therapeutics | 10-Q: Quarterly report
Edgewise Therapeutics | 8-K: Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Edgewise Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Morris Arlene
Edgewise Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Morris Arlene
Edgewise Therapeutics | DEFA14A: Others
Edgewise Therapeutics | 8-K: Current report
Edgewise Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer MOORE JOHN R
Edgewise Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Carruthers R Michael
Edgewise Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Derakhshan Behrad
Edgewise Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Russell Alan J
Edgewise Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Donovan Joanne M.
Edgewise Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer KOCH KEVIN
Edgewise Therapeutics | DEFA14A: Others
Edgewise Therapeutics | DEF 14A: Definitive information statements
Edgewise Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Edgewise Therapeutics | 10-K: Annual report
Edgewise Therapeutics | 8-K: Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Analysis
Price Target
No Data
